How to manage intravenous vinflunine in cancer patients with renal impairment: Results of a pharmacokinetic and tolerability phase i study

British Journal of Clinical Pharmacology

Volumn 77, Issue 3, 2014, Pages 498-508

  Isambert, Nicolas ^a   Delord, Jean Pierre ^b   Tourani, Jean Marc ^c   Fumoleau, Pierre ^a   Ravaud, Alain ^d   Pinel, Marie Claire ^e   Petain, Aurelie ^e   Nguyen, Thierry ^f   Nguyen, Laurent ^e  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d HÔPITAL SAINT ANDRÉ   (France)

^e INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^f UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

advanced metastatic solid tumours; pharmacokinetics; phase I; renal impairment; vinflunine

Indexed keywords

ADVANCED/METASTATIC SOLID TUMOURS; PHARMACOKINETICS; PHASE I; RENAL IMPAIRMENT; VINFLUNINE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRANCE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; KIDNEY DISEASES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME; TUBULIN MODULATORS; VINBLASTINE;

EID: 84894475296     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12218     Document Type: Article

References (27)

1. Hill BT, Fiebig HH, Waud WR, Poupon MF, Colpaert F, Kruczynski A,. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer 1999; 35: 512-520.
2. Kruczynski A, Colpaert F, Tarayre JP, Mouillard P, Fahy J, Hill BT,. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol 1998; 41: 437-447.
3. Kruczynski A, Poli M, Dossi R, Chazottes E, Berrichon G, Ricome C, Giavazzi R, Hill BT, Taraboletti G,. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer 2006; 42: 2821-2832.
4. Pourroy B, Honore S, Pasquier E, Bourgarel-Rey V, Kruczynski A, Briand C, Braguer D,. Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells. Cancer Res 2006; 66: 3256-3263.
5. Bennouna J, Delord JP, Campone M,. Vinflunine: a new microtubule inhibitor agent. Clin Cancer Res 2008; 14: 1625-1632.
6. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO,. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002; 20: 4713-4721.
7. Schutz FAAB, Bellmunt J, Rosenberg JE, Choueiri TK,. Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid. Expert Opin Drug Saf 2011; 10: 645-653.
8. Bennouna J, Fumoleau P, Armand JP, Raymond E, Campone M, Delgado FM, Puozzo C, Marty M,. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol 2003; 14: 630-637.
9. Frampton JE, Moen MD,. Vinflunine. Drugs 2010; 70: 1283-1293.
10. Lobert S, Puozzo C,. Pharmacokinetics, metabolites, and preclinical safety of vinflunine. Semin Oncol 2008; 35: S28-S33.
11. Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, Morere JF, Beuzeboc P, Deray G,. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007; 110: 1376-1384.
12. Launay-Vacher V,. Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. Semin Nephrol 2010; 30: 548-556.
13. Lalonde RL, Wagner JA,. Drug development perspective on pharmacokinetic studies of new drugs in patients with renal impairment. Clin Pharmacol Ther 2009; 86: 557-561.
14. Bonneterre J, Focan C, Mauriac L, Piccart M,. Phase I and pharmacokinetic study of Navelbine oral (NVBo) in patients with advanced breast cancer. Proc. 11th Internat. Congress on Anti-Cancer Chemotherapy, 133-Abst.S02-04. 2001.
15. Rickman PP,. Human experimentation. Code of ethics of the world medical association. Declaration of Helsinki. Br Med J 1964; 2: 177.
16. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.
17. Delord JP, Stupp R, Pinel MC,. Phase I study of vinflunine given as a 10 minute intravenous (IV) infusion an a weekly schedule in patients (pts) with advanced solid tumours. Proc Am Soc Clin Oncol 2001; 20: 111a.
18. Johnson P, Geldart T, Fumoleau P, Pinel MC, Nguyen L, Judson I,. Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. Invest New Drugs 2006; 24: 223-231.
19. Bennouna J, Breton JL, Tourani JM, Ottensmeier C, O'Brien M, Kosmidis P, Huat TE, Pinel MC, Colin C, Douillard JY,. Vinflunine-an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. Br J Cancer 2006; 94: 1383-1388.
20. Souquet P-J, Krzakowski R, Ramlou R, Sun XS, Lopez-Vivanco G, Puozzo C, Pouget JC, Pinel MC, Rosell R,. Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non small cell lung cancer. Clin Lung Cancer 2010; 11: 105-113.
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG,. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
22. Zorza G, Van Heugen JC, De Graeve J, Puozzo C,. Development of a sensitive liquid chromatography method coupled with a tandem mass spectrometric detection for the clinical analysis of vinflunine and 4-O-deacetyl vinflunine in blood, urine and faeces. J Chromatogr B 2007; 853: 294-302.
23. CHMP. Guideline on the investigation of bioequivalence. EMEA 2010.
24. CHMP. Note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function. EMEA 2004.
25. Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Winquist E, Morsli N, Salhi Y, Culine S, von der Maase H,. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27: 4454-4461.
26. Fumoleau P, Cortes-Funes H, Taleb AB, Chan S, Campone M, Pouget JC, Tubiana-Hulin M, Slabber CF, Caroff-Paraïso I, Alberts AS, Ben Ayed F,. Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy. Am J Clin Oncol 2009; 32: 375-380.
27. Vaughn DJ, Srinivas S, Stadler WM, Pili R, Petrylak D, Sternberg CN, Smith DC, Ringuette S, de Wit E, Pautret V, George C,. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer 2009; 115: 4110-4117